title: Continuation of trastuzumab beyond disease progression.
authors.forename: Filippo
authors.initials: F
authors.lastname: Montemurro
authors.forename: Roberto
authors.initials: R
authors.lastname: Faggiuolo
authors.forename: Stefania
authors.initials: S
authors.lastname: Redana
authors.forename: Michela
authors.initials: M
authors.lastname: Donadio
authors.forename: Monica
authors.initials: M
authors.lastname: Minischetti
authors.forename: Antonio
authors.initials: A
authors.lastname: Durando
authors.forename: Guido
authors.initials: G
authors.lastname: Vietti-Ramus
authors.forename: Roberta
authors.initials: R
authors.lastname: Buosi
authors.forename: Massimo
authors.initials: M
authors.lastname: Aglietta
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003657:Decision Making; D018450:Disease Progression; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab